0.05Open0.05Pre Close0 Volume506 Open Interest2.50Strike Price0.00Turnover337.96%IV57.17%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0340Delta0.0248Gamma114.40Leverage Ratio-0.0122Theta-0.0001Rho-3.89Eff Leverage0.0007Vega
Humacyte Stock Discussion
loading...
loading...
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
Pluristyx and Humacyte have entered into a license agreement to develop the BioVascular Pancreas (BVP) using Pluristyx’s clinical-grade PluriBank™ induced Pluripotent Stem Cell (iPSC) line. This agreement allows Humacyte to utilize Pluristyx’s panCELLa™ platform, which generates 'hypoimmune' cells for clinical implantation. The partnership aims to create insulin-producing cells...
$Humacyte(HUMA.US)$
loading...
No comment yet